Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisa Agostinetto

Showing results (41-50 of 76) with videos related to

Pageof 8
Sort By:
Cancer|July 9, 2026
Circulating tumor DNA in early breast cancer: Evidence, challenges, next stepsSerena Di Cosimo, Valentina Appierto, Carolina Reduzzi, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Journal of the National Cancer Institute|July 10, 2026
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysisRoberto Buonaiuto, Martina Pagliuca, Alessandra Longobardi, et al.
Breast Cancer Research and Treatment|April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialChristian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trialChiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
NPJ Breast Cancer|December 5, 2025
Personalized ctDNA detection and genomic profiling in the NeoRHEA StudyAlexandra Stanciu, Elisa Agostinetto, Andreas Papagiannis, et al.
Breast (Edinburgh, Scotland)|February 6, 2026
Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysisChiara Dauccia, Marco Bruzzone, Luca Arecco, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Future Oncology (London, England)|June 13, 2022
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breastElisa Agostinetto, Guilherme Nader-Marta, Marianne Paesmans, et al.
Pageof 8

Showing results (41-50 of 76) with videos related to

Sort By:
Pageof 8
Cancer|July 9, 2026
Circulating tumor DNA in early breast cancer: Evidence, challenges, next stepsSerena Di Cosimo, Valentina Appierto, Carolina Reduzzi, et al.
Journal of the National Cancer Institute|April 4, 2026
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trialElisa Agostinetto, Gabriella Gentile, Faye Samy, et al.
Journal of the National Cancer Institute|July 10, 2026
Impact of trop-2 expression on the efficacy of trop-2-targeted antibody-drug conjugates in metastatic breast cancer: a systematic review and meta-analysisRoberto Buonaiuto, Martina Pagliuca, Alessandra Longobardi, et al.
Breast Cancer Research and Treatment|April 28, 2025
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trialChristian Maurer, Elisa Agostinetto, Lieveke Ameye, et al.
European Journal of Cancer (Oxford, England : 1990)|June 17, 2026
Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trialChiara Dauccia, Maria Alice Franzoi, Cristina Saura, et al.
NPJ Breast Cancer|December 5, 2025
Personalized ctDNA detection and genomic profiling in the NeoRHEA StudyAlexandra Stanciu, Elisa Agostinetto, Andreas Papagiannis, et al.
Breast (Edinburgh, Scotland)|February 6, 2026
Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysisChiara Dauccia, Marco Bruzzone, Luca Arecco, et al.
JCO Precision Oncology|September 28, 2022
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease RelapseFrédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, et al.
Critical Reviews in Oncology/Hematology|August 10, 2023
Real-world clinical outcomes of patients with stage I HER2-positive breast cancer treated with adjuvant paclitaxel and trastuzumabVeronique Debien, Guilherme Nader Marta, Elisa Agostinetto, et al.
Future Oncology (London, England)|June 13, 2022
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breastElisa Agostinetto, Guilherme Nader-Marta, Marianne Paesmans, et al.
Pageof 8